诺思格(301333) - 诺思格调研活动信息

Group 1: Financial Performance - In 2023, the net profit attributable to shareholders is expected to be between 154 million and 174 million CNY, representing a year-on-year growth of 36% to 53% [2] - The net profit after deducting non-recurring gains and losses is projected to be between 123 million and 138 million CNY, indicating a year-on-year increase of 21% to 36% [3] Group 2: Strategic Goals - In 2024, the company aims to leverage its extensive experience to identify suitable investment targets and accelerate mergers and acquisitions [3] - The company plans to enhance internal management, improve refined management levels, and increase profitability [3] - There is a focus on expanding both domestic and international target markets to increase market share [3] Group 3: Competitive Advantages - The company's core competitive advantages are centered around "scientificity," showcasing innovative technical leadership in trial design and quality execution [3] - Key strengths include a strong expert team, an international management team, a professional execution team, comprehensive service capabilities across clinical stages, and a robust management system [3] Group 4: Market Positioning - The company prefers to select CRO clients based on scientific orientation, leading to more flexible and market-driven order pricing in the future [3] - Overall, the company's order prices are nearly on par with leading CRO companies, with some services priced slightly higher, aiming to secure orders based on technological advantages and reliable execution quality [3]